EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 29 / No 1 (Janvier 2013) Med Sci (Paris), 29 1 (2013) 65-73 References
Free Access
Issue
Med Sci (Paris)
Volume 29, Number 1, Janvier 2013
Page(s) 65 - 73
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2013291015
Published online 25 January 2013
  1. Semerano L, Boissier MC. Les anticorps monoclonaux dans les maladies immunes inflammatoires chroniques. Med Sci (Paris) 2009 ; 25 : 1108–1112. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Sibilia J. Protéine de fusion ou anticorps monoclonal: quel biomédicament choisir dans une maladie inflammatoire ? Med Sci (Paris) 2009 ; 25 : 1033–1038. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006 ; 15 : 308–318. [CrossRef] [PubMed] [Google Scholar]
  4. Mariette X. The B cell: a new therapeutic target in rheumatoid arthritis and other autoimmune diseases. Joint Bone Spine 2004 ; 71 : 357–360. [CrossRef] [PubMed] [Google Scholar]
  5. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the french autoimmunity and rituximab registry. Arthritis Rheum 2010 ; 62 : 2458–2466. [CrossRef] [PubMed] [Google Scholar]
  6. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010 ; 62 : 222–233. [CrossRef] [PubMed] [Google Scholar]
  7. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012 ; 64 : 1215–1226. [CrossRef] [PubMed] [Google Scholar]
  8. Wallace DJ, Kalunian KC, Petri MA, et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study. Arthritis Rheum 2010 ; 62 : 1452. [CrossRef] [Google Scholar]
  9. Wallace DJ, McKay J, Kelley L, et al. Long-term safety of epratuzumab in patients with moderate-to-severe systemic lupus erythematosus (SLE): 2-year interim data from an open-label re-treatment study. Ann Rheum Dis 2011 ; suppl : AB0885. [Google Scholar]
  10. Jacobi AM, Goldenberg DM, Hiepe F, et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008 ; 67 : 450–457. [CrossRef] [PubMed] [Google Scholar]
  11. Daridon C, Blassfeld D, Reiter K, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther 2010 ; 12 : R204. [CrossRef] [PubMed] [Google Scholar]
  12. Hikida M, Johmura S, Hashimoto A, et al. Coupling between B cell receptor and phospholipase C-gamma2 is essential for mature B cell development. J Exp Med 2003 ; 198 : 581–589. [CrossRef] [PubMed] [Google Scholar]
  13. Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 2005 ; 202 : 1363–1374. [CrossRef] [PubMed] [Google Scholar]
  14. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest 2002 ; 109 : 59–68. [PubMed] [Google Scholar]
  15. Ramanujam M, Wang X, Huang W, et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004 ; 173 : 3524–3534. [PubMed] [Google Scholar]
  16. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011 ; 63 : 3918–3930. [CrossRef] [PubMed] [Google Scholar]
  17. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011 ; 377 : 721–731. [CrossRef] [PubMed] [Google Scholar]
  18. Wallace DJ, Navarra S, Petri M, et al. Safety profile of Belimumab, a B-lymphocyte stimulator specific inhibitor, in phase 2 and 3 clinical trials of patients with active systemic lupus erythematosus. Arthritis Rheum 2011 ; 63 : 578. [Google Scholar]
  19. Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007 ; 56 : 4142–4150. [CrossRef] [PubMed] [Google Scholar]
  20. Pena-Rossi C, Nasonov E, Stanislav M, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 2009 ; 18 : 547–555. [CrossRef] [PubMed] [Google Scholar]
  21. Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF, corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012 ; 14 : R33. [CrossRef] [PubMed] [Google Scholar]
  22. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010 ; 62 : 3077–3087. [CrossRef] [PubMed] [Google Scholar]
  23. Mathian A, Koutouzov S. Interféron-alpha : une cytokine clé dans la physiopathologie du lupus systémique. Rev Med Interne 2008 ; 29 : 696–700. [CrossRef] [PubMed] [Google Scholar]
  24. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003 ; 197 : 711–723. [CrossRef] [PubMed] [Google Scholar]
  25. McBride J, Wallace D, Yao Z, et al. Dosedependent modulation of interferon regulated genes with administration of single, repeat doses of rontalizumab in a phase I, placebo controlled, double blind, dose escalation study in SLE. Arthritis Rheum 2009 ; 60 : 2072. [Google Scholar]
  26. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008 ; 10 : 202. [CrossRef] [PubMed] [Google Scholar]
  27. Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev 2012 ; 11 : 321–325. [CrossRef] [PubMed] [Google Scholar]
  28. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010 ; 62 : 542–552. [CrossRef] [PubMed] [Google Scholar]
  29. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008 ; 14 : 748–755. [CrossRef] [PubMed] [Google Scholar]
  30. Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011 ; 3 : 73ra19. [CrossRef] [PubMed] [Google Scholar]
  31. Charles N, Hardwick D, Daugas E, et al. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med 2010 ; 16 : 701–707. [CrossRef] [PubMed] [Google Scholar]
  32. Kaveri SV, Mouthon L, Bayry J. Basophils and nephritis in lupus. N Engl J Med 2010 ; 363 : 1080–1082. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.